Zacks Investment Research
16 Oct 2025, 14:11 UTC · 49w ago
Verdict
Headline takes no side. We score XERS +0.90 across four claims — strongly bullish.
+0.90strongly bullish
More positive than 96% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Xeris Biopharma (XERS) shares rose 14.2% to $9.27 in the last trading session on high volume.
More positive than 79% of claims this week
Analysts have revised the consensus EPS estimate for XERS 60.7% higher over the last 30 days.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 66% of claims this week
Xeris Biopharma is expected to report a 116.7% year-over-year increase in quarterly earnings per share.
So whatStrong projected growth in profitability supports a positive valuation trend.
More positive than 54% of claims this week
Xeris Biopharma is expected to see a 37% year-over-year increase in quarterly revenues to $74.35 million.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 96% of ticker scores this week
Shares jumped 14.2% on high volume due to positive growth prospects and strong earnings estimate revisions.
More negative than 62% of ticker scores this week
The stock finished the last trading session lower and has returned -2.7% over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
+5.4%
Price agrees with the score
$9.77 vs $9.27 close before publication (Oct 15) · not market-adjusted
XERS chart →
